Interestingly, there did not appear to be any suggestion of benefit for women with TNBC (HR = 1.25, 95 % CI 0.40–3.95), but there was for women with HER2+ breast cancer, although nonsignificant (HR = 0.21, 95 % CI 0.04–1.02). This evidence concerns the gene ERBB2 and breast cancer.